Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Iloprost

    go.drugbank.com/drugs/DB01088
    ApprovedInvestigational

    [A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties. … Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.

    Synonyms: (5E)-[3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E)-(3S,4RS)-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1H)-ylidene]pentanoic acid
  2. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than … Hydroxystilbamidine isethionate is also used in pathology for diagnostic purposes.

  3. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    (PHEIC) status on the West Africa Ebola outbreak. … Ebola virus vaccine is a vaccine used to prevent Ebola virus disease caused by _Zaire ebolavirus_ in adults, prevent outbreaks, and reduce the extent of the virus spreading in case of outbreaks.

    Synonyms: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP
  4. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. … [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA

  5. Drug

    Kanamycin

    go.drugbank.com/drugs/DB01172
    ApprovedInvestigationalVet approvedWithdrawn

    Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

    Synonyms: 4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-α-D-glucoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
  6. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

  7. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724] … Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.

    Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium Chloride
  8. Drug

    Dihydralazine

    go.drugbank.com/drugs/DB12945
    ApprovedWithdrawn

    Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  9. Drug

    Sulfadiazine

    go.drugbank.com/drugs/DB00359
    ApprovedInvestigationalVet approved

    One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

    Synonyms: N(1)-2-Pyrimidylsulfanilamide, N(1)-2-PyrimidinylsulfanilamideCategories: combinations of sulfonamides
  10. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … [L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967. It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.